YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Timothy A. Yap, David J. Kwiatkowski, Ibiayi Dagogo‐Jack, Michael Offin, Marjorie G. Zauderer, Robert A. Kratzke, Jayesh Desai, Amy Body, Michael Millward, Anthony W. Tolcher, Kanwal Raghav, Archie Thurston, Len Post, F. Andrew Dorr, Tracy Tang, Yufeng Li, Neelesh Sharma, Hedy L. Kindler
Topics & Concepts
MesotheliomaMedicineRefractory (planetary science)ProteinuriaInterimDrugUrologyInternal medicinePeripheral edemaClinical trialUrineOncologyPharmacologyAntagonistToxicityInterim analysisFood and drug administrationPazopanibAdverse effectCohortRetention ratePhases of clinical researchGastroenterologyPharmacokineticsCancer researchEdemaPeripheralKidneyHippo pathway signaling and YAP/TAZCancer-related gene regulation